As it is devoid of A-to-I editing functionality, ADAR3 mediates its effect on cancer by inhibiting RNA editing, mostly notably that of ADAR2-mediated glutamate receptor ionotropic AMPA2 (GRIA2) A-to-I editing (glutamine-to-arginine substitution at residue 607) in glioma and glioblastoma (Oakes et al., 2017; Zhang et al., 2018). Here, ADARB2 is linked to glioblastoma.